Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Anti-IL-17 mAbs herald new options in psoriasis

Nature Biotechnology volume 30, pages 475–476 (2012)Cite this article

Subjects

Brodalumab and ixekizumab exceeded expectations in psoriasis, but for this indication, there are very effective biologics for moderate to severe disease already in routine clinical use (Nat. Biotechnol. 29, 563–566, 2011). So new agents must continue to show good safety profiles if they are to capture a major piece of the estimated $3.5-billion market for biologics in psoriasis.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Author information

Authors and Affiliations

  1. Ann Arbor, Michigan

    Ken Garber

Authors
  1. Ken Garber
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Garber, K. Anti-IL-17 mAbs herald new options in psoriasis. Nat Biotechnol 30, 475–476 (2012). https://doi.org/10.1038/nbt0612-475

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0612-475

Further reading

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing